Is CVS Stock Worth Buying as Aetna Recovers but PBM Risks Persist?
Is CVS Stock Worth Buying as Aetna Recovers but PBM Risks Persist? The Globe and Mail
Covered in this story
Analyst targets on CVS Health
- Raymond James: at $83.8 · target $103 by Nov 2027 · Outperform via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $CVS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on CVS Health →Summary aggregated from The Globe and Mail's public RSS feed. The full reporting belongs to The Globe and Mail — please read it on their site.